Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has partnered with the University of Nottingham for in vivo testing of its aminoindane New Chemical Entity (NCE) pre-clinical program. The study, led by Dr. Madeleine King, will evaluate Awakn's co-lead aminoindane series for its potential to enhance social cognition and pro-social behaviors.
The research will use the Social Transmission of Food Preferences (STFP) test in rodent models over a two-month period, with results expected by the end of 2024. This collaboration follows Awakn's recent partnership with Eurofins Discovery for in vitro pharmacology testing of the same aminoindane series.
Awakn's aminoindane NCE program, developed with Graft Polymer (UK) Plc, aims to create new therapeutic options for trauma-related mental health disorders, particularly PTSD, which affects approximately 13 million adults in the U.S. and 20 million individuals across the U.S., UK, and Europe.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) ha stretto una partnership con l'Università di Nottingham per test in vivo del suo nuovo ente chimico (NCE) amminoindano nel programma pre-clinico. Lo studio, guidato dalla Dr. Madeleine King, valuterà la serie di amminoindano co-lead di Awakn per il suo potenziale nell migliorare la cognizione sociale e i comportamenti pro-sociali.
La ricerca utilizzerà il test di Trasmissione Sociale delle Preferenze Alimentari (STFP) in modelli rodentici per un periodo di due mesi, con risultati attesi entro la fine del 2024. Questa collaborazione segue la recente partnership di Awakn con Eurofins Discovery per test di farmacologia in vitro della stessa serie di amminoindano.
Il programma NCE amminoindano di Awakn, sviluppato con Graft Polymer (UK) Plc, mira a creare nuove opzioni terapeutiche per i disturbi mentali legati al trauma, in particolare il PTSD, che colpisce circa 13 milioni di adulti negli Stati Uniti e 20 milioni di individui tra Stati Uniti, Regno Unito e Europa.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) se ha asociado con la Universidad de Nottingham para pruebas in vivo de su nuevo ente químico (NCE) aminoindano en el programa preclínico. El estudio, liderado por la Dr. Madeleine King, evaluará la serie de aminoindano co-liderada de Awakn por su potencial para mejorar la cognición social y los comportamientos pro-sociales.
La investigación utilizará la prueba de Transmisión Social de Preferencias Alimentarias (STFP) en modelos de roedores durante un período de dos meses, con resultados esperados para finales de 2024. Esta colaboración sigue a la reciente asociación de Awakn con Eurofins Discovery para pruebas de farmacología in vitro de la misma serie de aminoindano.
El programa NCE de aminoindano de Awakn, desarrollado con Graft Polymer (UK) Plc, tiene como objetivo crear nuevas opciones terapéuticas para los trastornos mentales relacionados con trauma, en particular el PTSD, que afecta a aproximadamente 13 millones de adultos en los EE. UU. y 20 millones de individuos en EE. UU., Reino Unido y Europa.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF)는 노팅엄 대학교와 협력하여 아미노인단(New Chemical Entity, NCE)에 대한 생체 내(in vivo) 테스트를 진행합니다. Dr. Madeleine King가 이끄는 이 연구는 Awakn의 공동 주도 아미노인단 시리즈가 사회적 인지와 친사회적 행동을 향상시킬 가능성을 평가할 것입니다.
이번 연구는 두 달 동안 설치류 모델에서 사회적 음식 선호 전이(Social Transmission of Food Preferences, STFP) 테스트를 사용할 예정이며, 결과는 2024년 말에 나올 것으로 예상됩니다. 이 협력은 Awakn이 Eurofins Discovery와 아미노인단 시리즈의 시험관 내(in vitro) 약리학 테스트를 위한 최근 파트너십을 맺은 뒤 진행됩니다.
Awakn의 아미노인단 NCE 프로그램은 Graft Polymer(UK) Plc와 협력하여 개발되었으며, 특히 미국에서 약 1300만 명의 성인과 미국, 영국, 유럽 전역에서 2000만 명의 사람들에게 영향을 미치는 PTSD와 같은 외상 관련 정신 건강 장애에 대한 새로운 치료 옵션을 만드는 것을 목표로 하고 있습니다.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) a conclu un partenariat avec l'Université de Nottingham pour des tests in vivo de son nouvel entité chimique (NCE) aminoindane dans le cadre de son programme préclinique. L'étude, dirigée par la Dr. Madeleine King, évaluera la série d'aminoindane co-dirigée d'Awakn pour son potentiel à améliorer la cognition sociale et les comportements pro-sociaux.
La recherche utilisera le test de Transmission Sociale des Préférences Alimentaires (STFP) sur des modèles de rongeurs pendant une période de deux mois, avec des résultats attendus d'ici la fin de 2024. Cette collaboration fait suite au récent partenariat d'Awakn avec Eurofins Discovery pour des tests de pharmacologie in vitro de la même série d'aminoindane.
Le programme NCE d'aminoindane d'Awakn, développé avec Graft Polymer (UK) Plc, vise à créer de nouvelles options thérapeutiques pour les troubles de santé mentale liés au traumatisme, en particulier le PTSD, qui affecte environ 13 millions d'adultes aux États-Unis et 20 millions d'individus aux États-Unis, au Royaume-Uni et en Europe.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) hat sich mit der Universität Nottingham zusammengetan, um in vivo-Tests für sein neues chemisches Produkt (NCE) Aminoindan im präklinischen Programm durchzuführen. Die Studie, geleitet von Dr. Madeleine King, wird die co-lead Aminoindan-Serie von Awakn auf ihr Potential zur Verbesserung der sozialen Kognition und prosozialen Verhaltensweisen bewerten.
Die Forschung wird den Test zur sozialen Übertragung von Lebensmittelpräferenzen (STFP) über einen Zeitraum von zwei Monaten an Nagetiermodellen durchführen, wobei mit Ergebnissen bis Ende 2024 gerechnet wird. Diese Zusammenarbeit folgt auf die kürzliche Partnerschaft von Awakn mit Eurofins Discovery für in vitro-Pharmakologietests derselben Aminoindan-Serie.
Das Aminoindan-NCE-Programm von Awakn, das gemeinsam mit Graft Polymer (UK) Plc entwickelt wurde, zielt darauf ab, neue therapeutische Optionen für traumaassoziierte psychische Störungen, insbesondere für PTSD, zu schaffen, das rund 13 Millionen Erwachsene in den USA und 20 Millionen Menschen in den USA, Großbritannien und Europa betrifft.
- Partnership with University of Nottingham for in vivo testing of aminoindane NCE program
- Potential to enhance social cognition and pro-social behaviors
- Targeting PTSD, which affects 20 million individuals across the U.S., UK, and Europe
- Results expected by the end of 2024
- Recent partnership with Eurofins Discovery for in vitro pharmacology testing
- None.
Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a new research partnership with the University of Nottingham, UK. This collaboration focuses on evaluating Awakn's co-lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.
The study will be led by Dr. Madeleine King, Assistant Professor in the School of Life Sciences in the Faculty of Medicine & Health Sciences at the University of Nottingham, a globally recognized institution for its cutting-edge neuroscience research. Dr. King, an expert in behavioral neuroscience with over 20 years of experience, is renowned for her contributions to translational research in psychiatric disorders. The study will use the Social Transmission of Food Preferences (STFP) test in rodent models. Conducted over a two-month period, the preclinical trials will explore varying dosages, with results expected by the end of 2024.
Awakn's aminoindane NCE program, developed in collaboration with Graft Polymer (UK) Plc, focuses on creating new therapeutic options for trauma-related mental health disorders, particularly PTSD. PTSD affects approximately 13 million adults in the U.S. and 20 million individuals across the U.S., UK, and Europe. This partnership, originally announced on July 18, 2024, builds on Awakn's commitment to addressing these urgent medical needs.
This progress follows Awakn's recent partnership with Eurofins Discovery for in vitro pharmacology testing of the same aminoindane series. The selection of Eurofins marked a critical milestone, and this next phase with the University of Nottingham underscores Awakn's rapid advancements in developing next-generation treatments for mental health disorders.
Anthony Tennyson, CEO of Awakn Life Sciences, stated: "This is a pivotal step forward in our Aminoindane NCE program. We believe this novel aminoindane has the potential to revolutionize mental health treatment, offering a safer alternative for trauma-related mental health disorders such as PTSD. Our collaboration with the University of Nottingham reinforces our commitment to advancing science-backed, life-changing therapies."
Dr King, from the School of Life Sciences at the University of Nottingham said: "I'm delighted that Awakn Life Sciences have chosen to collaborate with the University of Nottingham. I'm excited to be involved in this research, which has real potential to improve patient health."
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics targeting substance use and mental health disorders. Awakn has a near-term focus on AUD, a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
www.awaknlifesciences.com | LinkedIn | X (formerly Twitter)
About the University of Nottingham
Ranked 32 in Europe and 16th in the UK by the QS World University Rankings: Europe 2024, the University of Nottingham is a founding member of Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 - the third time is has been given the honour since 2018 - and by the Daily Mail University Guide 2024.
The University is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The University is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.
We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city's two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.
Notice Regarding Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedarplus.ca. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
416-270-9566
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226631
FAQ
What is the purpose of Awakn's partnership with the University of Nottingham?
Who is leading the study at the University of Nottingham for Awakn (AWKNF)?
What testing method will be used in the Awakn (AWKNF) study at the University of Nottingham?
When are the results of Awakn's (AWKNF) study with the University of Nottingham expected?
What mental health disorder is Awakn (AWKNF) targeting with its aminoindane NCE program?
